Escitalopram and the Risk of Serious Adverse Events

The goal of this population-based cohort study is to assess the safety of initiating a new outpatient prescription of 10mg/day of Escitalopram (higher dose) compared to 5 mg/day (lower dose) in adults over the age of 65 with low kidney function. Primary question Whether initiating a new outpatient prescription of a higher dose of Escitalopram (10mg/day) compared to a lower dose (5 mg/day) in older adults with low kidney function (an eGFR \<45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization, all-cause emergency department visit, or all-cause mortality?

NCT Number	NCT07274241
Lead Sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions	Chronic Kidney Disease (CKD), Elderly, Outpatient
Enrollment	12,145 participants
Start Date	2008-01-01
Primary Completion	2025-01-01 (estimated)
Study Completion	2025-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-30